Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that minoxidil significantly reduced supine diastolic pressure in 94% of patients with severe essential hypertension within 4 weeks, but some patients experienced side effects such as increased hair growth and fatigue.

This study found that combining Hebai Formula Granule Wash with minoxidil tincture was more effective than minoxidil alone in treating androgenic alopecia, as it significantly improved clinical efficacy, promoted new hair growth, and reduced hair loss in patients.

This study found that a new propylene glycol-free 5% minoxidil lotion demonstrated good clinical efficacy and very good cosmetic acceptability and tolerability after six months of use in patients with androgenetic alopecia, showing results comparable to traditional formulations containing propylene glycol.

The abstract describes a journal that covers a wide range of topics from basic research to dermo-aesthetics, emphasizing multidisciplinary approaches and scientific rigor across subjects like molecular biology, gene therapy, and dermocosmetics, but provides no specific study results.

In this study, researchers at Zaporozhye State Medical University developed a 2% minoxidil cream-mask and found it thermally stable during manufacturing, with no chemical interactions between active and base components, signaling potential for effective hair growth stimulation treatments.

In this study, oral minoxidil at a dose of 1.25 mg/day for 24 weeks was examined as a sole treatment for androgenetic alopecia in 32 patients, including those who had not responded to prior topical minoxidil or oral finasteride therapies.

This study found that topical minoxidil increases hair density more than placebo in both men and women with androgenetic alopecia, achieving about 21 additional hairs per cm² after 16 to 48 weeks, while oral and topical versions show similar efficacy but different side effects.

Most young patients found oral minoxidil helpful for hair loss and were willing to continue using it.

This study found that the gelatinous minoxidil 1% shampoo demonstrated thixotropic properties and mechanical stability, suggesting predictable long-term consistency and effective distribution on the scalp.

This source highlights topical minoxidil as the first-line treatment for androgenetic alopecia in both genders and finasteride for men, while also identifying dutasteride, low-dose oral minoxidil, and topical finasteride as promising future options.

This review discusses the use of topical minoxidil for various types of alopecia and reports mixed evidence on its efficacy, with stronger support noted for conditions like eyebrow hypotrichosis and chemotherapy-induced alopecia.

This study found that topical 5% minoxidil solution is effective and well tolerated for promoting hair growth in Korean men with androgenetic alopecia over 24 weeks.

Combining oral minoxidil and bicalutamide may help improve hair growth in adolescent girls.

Minoxidil effectively controls blood pressure in severe cases, but has serious side effects and causes hair growth in women.

This study found that using topical minoxidil did not affect the percentage of hair survival after transplantation for androgenetic alopecia, but did reduce initial postoperative hair shedding in 60% of grafts.

This case series reports the experience of using oral minoxidil at 1.25 mg/day in 32 patients with male androgenetic alopecia, noting both therapeutic effects and potential adverse reactions.

This study explored nanoemulsions of minoxidil, revealing that a 5% minoxidil nanoemulsion improved hair growth and follicle count in animal studies compared to commercial minoxidil solutions, even without significant differences in permeation rates.

This study confirms that twice-daily application of 5% minoxidil solution, Carexidil®, is effective for androgenetic alopecia in both men and women, showing results after 6 months.

This article discusses nonprescription treatments for hereditary pattern hair loss, highlighting minoxidil's role and guidelines for use, but reports no new clinical results.

This study observed that low-dose oral minoxidil and topical minoxidil 5% solution both improved hair density in women with female-pattern hair loss, but oral minoxidil may offer advantages in reducing hair shedding.

This case report discusses a 45-year-old Japanese man who developed myocardial infarction while using 1% topical minoxidil for baldness, highlighting the need for caution in patients with cardiovascular disorders.

This study found that nanoparticles containing minoxidil and betamethasone improved drug delivery to hair follicles, with lipidic nanoparticles significantly enhancing minoxidil and betamethasone penetration compared to control, making them a promising option for alopecia areata treatment with reduced side effects.

This case report describes a woman who experienced frontal edema after topical minoxidil application following mesotherapy, noting that excessive absorption of minoxidil may cause localized vasodilatory side effects.

This abstract does not report specific findings but notes that topical minoxidil, available in 2% and 5% formulations, is widely used and FDA-approved for treating androgenetic alopecia in both men and women, with a strong safety profile.

Topical minoxidil effectively stimulates hair growth in men with hair loss.

In this study, 56% of men meeting specific criteria for hair loss experienced cosmetically acceptable hair growth with 2% topical minoxidil after one year, while frontotemporal hair loss did not improve.

This study found that a topical solution of caffeine and minoxidil 2.5% was more effective in treating androgenetic alopecia than minoxidil 2.5% alone.

This study found that adding 7% chamomile extract to 5% minoxidil solution reduced cutaneous side effects like itching, scaling, and erythema in men with androgenic alopecia compared to using minoxidil alone.

This study found that treatments with 5% minoxidil, with or without latanoprost, were effective in controlling hair loss and increasing hair strand count in patients with telogen effluvium or androgenic alopecia.